Fels B, Kusche-Vihrog K.
It takes more than two to tango: mechanosignaling of the endothelial surface
Pflugers Arch. 2020 doi: 10.1007/s00424-020-02369-2

Cosgun ZC, Fels B, Kusche-Vihrog K.
Nanomechanics of the Endothelial Glycocalyx: From Structure to Function
Am J Pathol. 2020 doi: 10.1016/j.ajpath.2019.07.021

Jelkmann W
Autologous Red Blood Cell Transfusions in Clinics and their Misuse in Sports. Dtsch Z Sportmed 71: 62-68, 2020

Jelkmann W
Erythropoietin Doping: Cardiovascular Effects in Athletes. Ann Sports Med Res 7(1): 1142, 2020


Jelkmann W
Erythropoietin: Novelties in anti-doping research
Curr Opin Endocrine and Metabol Res 9: 28-33, 2019


Jelkmann W
Activin receptor ligand traps in chronic kidney disease
Current Opin Nephrol Hypertens. 2018 Sep;27(5):351-357. doi: 10.1097/MNH.0000000000000433

Kosyna FK, Depping R
Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport
Cells 2018 Nov 21;7(11). pii:E221 doi: 3390/cells7110221. Review.


Aapro M, von Haehling S, Jelkmann W, Link H, Meybohm P, Seiler S, Zacharowski K
Anämie- und Blutmanagement: Neubewertung in verschiedenen Indikationen
Dtsch Ärztebl 114(48), 2017 DOI: 10.3238/PersOnko/2017.12.01.17

Depping R, Oster H
Interplay between environmentally modulated feedback loops - hypoxia and circadian rhythms - two sides of the same coin?
FEBS J, 284(22):3801-3803, 2017

Jelkmann W
Watch out for a revival of peginesatide in sports
Drug Test Anal 9(2): 157-160, 2017

Mandl M, Depping R
Hypoxic Upregulation of ARNT (HIF-1β): A Cell-Specific Attribute with Clinical Implications

Hypoxia and Human Diseases , ISBN 978-953-51-2896-0


Jelkmann W, Thevis M
Could Nickel Become a Novel Erythropiesis-Stimulating Compound for Cheating Athletes?

Dtsch Z Sportmed 67:253-254, 2016

Pagel H
Hände weg von Nahrungsergänzungsmitteln!
Doping 3(2): 40-43, 2016

Jelkmann W
Features of Blood Doping

Dtsch Z Sportmed67: 255-62, 2016

Schmidt K, Windler R, de Wit C
Communication Through Gap Junctions in the Endothelium
Adv Pharmacol 77: 209-40, 2016

von Fallois M, Depping R
Radiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models
Strahlenther Onkol 2016 [Epub ahead of print]

Jelkmann W
Biosimilars - ähnlich, aber nicht gleich.
Kompendium Biosimilars. Thieme, Stuttgart, 1: 6-10, 2016

Baumann R, Depping R, Delaperrier M, Dunst J
Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?Expert Rev Anticancer Ther 2016 [Epub ahead of print]

Schmid H, Jelkmann W

Investigational therapies for renal disease-induced anemia

Expert Opin Inverstig Drugs 25(8): 901-16, 2016



Depping R, Jelkmann W, Kosyna FK
Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing

J Mol Med (Berl) 93(6):599-608 doi: 10.1007/s00109-015-1276-0, 2015



Jelkmann W

The ESA scenario gets complex: from biosimilar epoetins to activin traps

Nephrol Dial Transplant 30:553-559, 2015


Pries AR, Badimon L, Bugiardini R, Camici PG, Dorobantu M, Duncker DJ, Escaned J, Koller A, Piek JJ, de Wit C

Coronary vascular regulation, remodelling and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation

Eur Heart  pii:ehv100, 2015




Ebert B, Jelkmann W
Intolerability of cobalt salt as erythropoietic agent.
Drug Test Anal 6(3): 185-9, 2014


Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W

Progress in detecting cell-surface protein receptors: the erythropoietin receptor example

Ann Hematol 93: 181-192, 2014




Mandl M, Depping R

Hypoxia-inducible ARNT (HIF-1β): a rare exception?

Mol Med 10.2119/molmed.2014.00032 [Epub ahead of print]



Jelkmann W

Xenon Misuse in Sports-Increase of Hypoxia-Inducible Factors and Erythropoietin, or Nothing but "Hot Air"?

Dtsch Z Sportmed 65:267-271, 2014


Windler R, de Wit, C

The Ca2+-dependent K-channel KCa3.1 as a therapeutic target in cardiovascular disease
Eur Heart J Suppl 16: A30-A32, 2014




Jelkmann I, Jelkmann W
Impact of erythropoietin on intensive care unit patients
Transfus Med Hemother 40:310-318, 2013

Jelkmann W

Körpereigene Produktion von Erythropoietin
Dtsch Z Sportmed 64:327-332, 2013


Jelkmann W
Physiology and pharmacology of erythropoietin
Transfus Med Hemother 40:302-309, 2013

Jelkmann W, Elliott S
Erythropoietin and the vascular wall: The controversy continues
NutrMetab Cardiovasc 23:37-43, 2013


Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Manfrini O,
Koller A, Pries A, Cenko E, Bugiardini R
Presentation, management, and outcomes of ischaemic heart disease in women
Nat Rev Cardiol 10:508-518, 2013



Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
Br J Cancer 106(7):1249-58, 2012

Jelkmann W

Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments
Expert Opin Biol Ther 12 (5):581-92, 2012

Jelkmann W
The disparate roles of cobalt in erythropoiesis, and doping relevance
Open J Hematol, 3-6, 2012

Jelkmann W
TREAT und die Frage: "Fördern ESA die Tumorprogression?"
Spektr Nephrol 25(3):21-25, 2012

Jelkmann W
The elusive erythropoietin receptor (Letter)
Nephrol Dial Transplant 27(88): 3369, 2012

Jelkmann W
Erythropoietin gene doping: Facts and fictions
Sportwiss 42: 280-285, 2012

Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights
Kidney Int 81(8):727-32, 2012



de Wit C

The endothelium at the brink of calamity in storage disease: more than
just overloaded with junk? (invited editorial)

Cardiovasc Res 89, 258-259, 2011


Jelkmann W, Lundby C

Blood doping and its detection

Blood 118(9): 2395-404, 2011


Jelkmann W

Blutdoping: Grundlagen, Nachweis und der Problemfall Pechstein

Spektr Nephrol 24(2): 17-21, 2011


Jelkmann W

Regulation of erythropoietin production

J Physiol 598.6, 1251-1258, 2011


Jelkmann W

Translationale Forschung: Stellenwert von EPO in der Wundheilung
DGPW-Journal 42: 34-38, 2011

Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Hall A, Koller
A, Marzilli M, Pries A, Bugiardini R
Ischemic Heart Disease in Women: Are There Sex Differences in
Pathophysiology and Risk Factors?

Cardiovasc Res 90, 9-17, 2011



de Wit C, Griffith TM

Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses

Pflügers Arch 459: 897-914, 2010



Jelkmann W.
Biosimilar epoetins and other follow-on biologics: Update on the European experiences
Am J Hematol. 85: 771-780, 2010


Jelkmann W
Claudia Pechstein, ein Fall von Blutdoping? (eingel. Kommentar)
Dtsch Z Sportmed 61: 243-4, 2010


Jelkmann W.
Erythropoietin: back to basics
Blood 115(21):4151-2, 2010



Jelkmann W
The future of biosimilars
Hosp Pharm Eur 48: 32-4, 2010



Jelkmann W
Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts
Curr Med Chem 16: 1236-47, 2009



Jelkmann W
Efficacy of recombinant erythropoietins: is there unity of international units?
Nephrol Dial Transplant 24: 1366-8, 2009

Paus R, Bodo E, Kromminga A, Jelkmann W
Erythropoietin and the skin: A role for epidermal oxygen sensing?
BioEssays 31: 344-8, 2009



de Wit C, Boettcher M, Schmidt VJ
Signaling across myoendothelial gap junctions - Fact or fiction?
Cell Commun Adhes 15: 231-45, 2008

Jelkmann W
Developments in the therapeutic use of erythropoiesis stimulating agents.
Br J Haematol 141: 287-97, 2008


Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ
The erythropoietin receptor in normal and cancer tissues.
Crit Rev Oncol Hematol 67: 39-61, 2008

Pries AR, Habazettl H, Ambrosio G, Hansen PR, Kaski JC, Schächinger V,
Tillmanns H, Vassalli G, Tritto I, Weis M, de Wit C, Bugiardini R
A review of methods for assessment of coronary microvascular disease in
both clinical and experimental settings

Cardiovasc Res 80: 165-74, 2008

Schmidt VJ, Wölfle SE, Boettcher M, de Wit C
Gap junctions synchronize vascular tone within the microcirculation
Pharmacol Rep 60: 68-74, 2008


Schön MR, Hogrebe E, Hengstler JG, Donaubauer B, Faber SC, Bauer A, Pietsch UC, Jelkmann W, Thiery J, Hauss JP, Tannapfel A
Erythropoietin stimulates hepatocyte regeneration after liver resection.
Excli J 7: 79-92, 2008



Brügge K, Jelkmann W, Metzen E

Hydroxylation of Hypoxia-Inducible Transcription Factors and Chemical Compounds Targeting the HIF-alpha Hydroxylases.

Curr Medicinal Chem 14: 1853-1862, 2007



de Wit C
Closing the gap at hot spots (invited editorial)
Circ Res 100: 931-933, 2007

de Wit C, Wölfle SE
EDHF and gap junctions: Important regulators of vascular tone within the microcirculation.
Curr Pharm Biotechnol 8: 11-25, 2007


Dunst J, Metzen E, Rades D
Erythropoietin in der Strahlentherapie.
Onkologe J 13:143-149, 2007

Jelkmann W
Control of erythropoietin gene expression and its use in medicine.
Methods Enzymol 435: 179-97, 2007


Jelkmann W
Erythropoietin after a century of research: younger than ever.
Eur J Haematol 78: 183-205, 2007

Jelkmann W
Novel erythropoietic agents: A threat to sportsmanship.
Medicina Sportiva 11: 32-42, 2007

Jelkmann W, Laugsch M
 Problems in identifying functional erythropoietin receptors in cancer tissue (Letter).
J Clin Oncol 25: 1627-1628, 2007

Jelkmann W
Recombinant EPO production-points the nephrologist should know.
Nephrol Dial Transplant 22: 2749-53, 2007



de Wit C, Hoepfl B, Wölfle SE 
Endothelial mediators and communication through vascular gap junctions.
Biol Chem 387: 3-9, 2006

de Wit C, Wölfle SE, Hoepfl B
Connexin-dependent communication within the vascular wall: Contribution to the control of arteriolar diameter.
Adv Cardiol 42: 268-283, 2006



Jelkmann W
Effects of erythropoietin on brain function.
Curr Pharm Biotechnol 6: 65-79, 2005


Jelkmann W, Wagner KF

Erythropoietic and non-erythropoietic actions of erythropoietin.

Recent Res Devel Haematol 2: 33-59, 2005


Rossert J; Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB)
Erythropoietin-induced, antibody-mediated pure red cell aplasia.
Eur J Clin Invest 35: 95-9, 2005






de Wit C

Connexins pave the way for vascular communication.

News Physiol Sci 19: 148-53 , 2004


Metzen E, Ratcliffe PJ

HIF hydroxylation and cellular oxygen sensing.

Biol Chem. 385: 223-30, 2004


Jelkmann W , Wagner K

Beneficial and ominous aspects of the pleiotropic action of erythropoietin.

Ann Hematol 83: 673-86, 2004


Jelkmann W

Molecular biology of erythropoietin.

Intern Med 43: 649-59, 2004


Pagel H, Hoffmann G, Fuchs D, Schobersberger W

On the Mechanisms of the Neopterin-induced Suppression of Renal Erythropoietin Production.

Pteridines 15: 28-32, 2004




Jelkmann W


J Endocrinol Invest 26: 832-837, 2003


Jelkmann W

The metabolic fate of circulating erythropoietin: Insights from the pharmacokinetics of recombinant human erythropoietin and novel erythropoiesis-stimulating protein.

Clin Impl Anemia Oncol 1: 7-9, 2003





Jelkmann W 

The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.

Eur J Haematol 69: 265-74, 2002


Klinger MH, Jelkmann W

Review: role of blood platelets in infection and inflammation.

J Interfer Cytokine Res 22: 913-22, 2002

Wolber EM, Jelkmann W

Thrombopoietin: the novel hepatic hormone.

News Physiol Sci 17: 6-10, 2002